Τόμος 21 (2007) – Τεύχος 1 – Άρθρο 12 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 21 (2007) – Issue 1 – Article 12 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Technological Educational Institution (T.E.I.) of Athens, Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

–      Abraha E., Fuller L., Vivier A., et al.: Serum S-100 protein? A potencially useful prognostic marker in coutaneous melanoma. Br J. Dermatol. 137: 381-385(1997)

–      Al-Awadhi A., Ohisi S., Al-Zaid N., et al.: Serum concentrations of interleukin 6, osteocalcin, intact par hormone, and markers of bone resorption in patients with rheumat arthritis. J Rheumatol. 26: 1250-1256 (1999)

–      Ballesta A., Molina R., Filella X., et al.: Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumor Biol. 16: 32-41 (1995)

–      Buer X., Probst M., Franzke A., et al.: Elevated serum levels of S-100 and survival in metastatic malignant melanoma. Br J. Cancer 75: 1373 -1376 (1997)

–      Buzald A., Tinoco L., Jenendiroba D., et al.: Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J. Clin. Oncol. 13: 2361-2368 (1995)

–      Catalona W., Partin A., Stawin K., et al.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease? A prospective multicenter clinical trial. JAMA 279: 1542-1547 (1998)

–       Chaniotis D., Karageorgos G., Petropoulos P., Chaniotis F.: Effect of digestive and pulmonary system infections on renal function. Rev. Clin. Pharmacol. Pharmacokinet.Int.. Ed. 20: 43-48 (2006)

–       Chaniotis F.I., Chaniotis D.I.: Cardiac cachexia. Hellenic J. Cardiol. 38: 94-98 (1997)

–      Crawford E., Schutz M., Clejan S., et al.: The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267: 2227-2228 (1992)

–      DeVita V., Hellman S., Rosenberg S.: CANCER, Principles and Practice of Oncology. Lippincott, Williams and Wilkins, 2001

–      Elledge G., McGulre W.: Prognostic factors and therapeutic decisions in axillary node-negative breast. Rev. Med. 44: 201-210 (1993)

–      Fletcher R.: Carcinoembryonic antigen. Ann. intern. Med. 104: 63-73 (1996)

–      Gion M, Mone R., Leon A., et al.: Comparison of the diagnostic accuracy of CA 27.29 and CA 15-3 in primary breast cancer. Clin. Chem. 45: 630-637 (1999)

–      Hayes D., Zurafski V., et al.: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. din. Oncol. 4 1542-1550 (1986)

–      Henze G., Dummer R., Joller-Jemeika H., et al.: Serum S-100: a marker for disease monitoring in metastatic melanoma. Dermatology 194: 208-212 (1997)

–      Huhtala M., Kahampas K., Seppala M., et al.: Excretion of a tumor-associated TAH in urine of patients with gynecological malignancy. Inter. J Cancer 31: 711-714 (1983)

–      Isola J., Visacorp T., Holli K., et al.: Association of p53 expression with other prognostic factors survival in node-negative breast cancer. J Cell. Biochem. (Suppl. 16D): 101 (1992)

–      Jarvisalo X., Hakama M., Knekt P., et al.: Serum tumor markers CEA, CA 50, TA1T and NSE in lung cancer screening. Cancer 71: 1982 -1988 (1993)

–      Johnson P.: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Cm. Liver Dis. 5: 145-159 (2000)

–      Kamell R., von Schoultz E., Hansson L., et al.: S-100 protein, 5-S-cysteinyldopa and hydroxy6-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 7: 393-399 (1997)

–      Koeler G., Milstein C.: Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256: 495-496 (1975)

–      Lasson A., Borgstrorn A., Ohlsson K.: Elevated pancreatic secretory trypsin inhibiter levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand. J Gastroenterol. 21: 1275-1280 (1986)

–      Lotnicker M., Pavesi F., Scarabelli M.: Tumor associated antigens CA 15-3 and CA 12-5 in ovarian cancer. Markers 6: 115 (1991)

–      Malkasian G., Knapp R., Lavin P., et al.: Preoperative evaluation of serum CA 12-5 levels in postmenopausal and postmenopausal patients with pelvic masses’ discrimination of benign from malignant disease. Am. J. Obstet. Gynecol. 159: 341-346 (1988)

–      Massaron S., Seregni E., Luksch R., et al.: Neuron-specific enolase evaluation in patients with neuroblastoma. Tumor Biology 19: 261-268 (1998)

–      McGulre W., Tandon A., Alfred D., et al.: How to use prognostic factors in axillary breast cancer patients. J Nat Cancer Inst. 82: 1006 -1007 (1990)

–      Michael H., Torosian M.: The clinical usefulness and limitations of tumor markers. Surg. Gynecol. Obstet. 166: 567-579 (1988)

–      Missotten G., Tang N., Korse C., et al.: Prognostic value of S-100 (beta) serum concentration in patients with uveal melanoma. Arch. Ophthalmol. 121: 1117-1119 (2003)

–      Oesterling X., Martin S., Bergstralh, et al.: The use of prostatic specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60 (1993)

–      Partin A., Carter H., Chan D., et al.: Prostate specific antigen in the staging of localized prostate cancer? Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 143: 747-752 (1990)

–      Partin A., Yoo J, Carter H., et al.: The use of PSA clinical stage in men with localized prostate cancer. J. Urol. 150: 110-114 (1993)

–      Pasanen P., Eskelinen M., Partanen E.L., et al.: Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res. 15: 2731-2737 (1995)

–      Pectasides D., Bafaloucos D., Antoniou F., et al.: TPA, TATI, CEA, AFP, b-HCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am. J Cm. Oncol. 19: 271-277 (1996)

–      Peters-Engl C., Buxbaum P., Ogris E., et al.’ TATI and cancer antigen CA 12-5 in patients with early-stage endometrial cancer. Anticancer Res. 18: 4635-4639 (1998)

–      Piantino P., Arosaio E.: TATI in gastrointestinal cancer and related benign diseases. Scand. J Clin. Labors Invest. 51: 67-69 (1991)

–      Stanmey T., Yang N., Hay A., et al.: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J Med. 317: 909-916 (1987)

–      Stenman U., Koivunen E., Itkonen O., et al.: Clinical use and biological function of TATI. Pp. 351-361, Edizione Minerva Medica S.P.A., Torino, 1993

–      Tchetgen M., Oesterling J.: The effect of prostatitis, urinary refentio in, ejaculation and ambulation of the serum prostate-specific antigen concentration. Urol. Clin. North Am. 24: 283-291 (1997)

–      Tramonti G., Ferdeghini M., Donatio C., et al.: Serum level of five tumor markers (TATI, SCC, Cyfia 21-1, TPA, TPS) and renal function. Intern. Symposium of the Impact of Biotechnology on Prediction, Prevention and Treatment of Cancer, Nice France, Oct. 24-27, 1998

–      Tripatzis L.: Monoclonical antibodies. Medical Sep. No 4 68-72 (1989)

–      Wibe E., Hannisdal E., Paus E., et al.: Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur J. Cancer 28A: 1692-1695 (1992)

–      For moreover data regarding the classification of cancer markers, it can find no one in the web pages’

http://www.asco.org (Am. Soc. of Clin. One. – ASCO) //www.ahsmedicare.com/medical review appeals (Associated Hospital Service-AHS) l/libraryumsmededu/medi-immutum //www.empiremedicare.com/

while for abundance of information in the web pages of international organisms of health, pharmaceutical houses, etc.

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr